Measurement of serum NTproANP concentration successfully predicted left ventricular hypertrophy and hemodynamic changes in Sprague-Dawley rats administered a PPARalpha/gamma dual agonist.
Do natriuretic peptides and imaging detect left ventricular hypertrophy induced by a PPAR alpha/gamma dual agonist in Sprague-Dawley rats?
Natriuretic peptides, particularly NTproANP, along with imaging, are effective biomarkers for the early detection and monitoring of left ventricular hypertrophy induced by PPAR agonists in rats.
Chronic treatment with suprapharmacologic doses of peroxisome proliferator-activated receptor (PPAR) agonists has a known potential for causing left ventricular hypertrophy (LVH). The mechanism by which LVH develops is not well understood nor are biomarkers of it well characterized. Natriuretic peptides are important regulators of cardiac growth, blood volume, and arterial pressure and may be useful biomarkers of LVH and hemodynamic changes that precede it. We measured amino-terminal pro-atrial natriuretic peptide (NTproANP), amino-terminal pro-brain natriuretic peptide (NTproBNP), and cardiac troponin I (cTnI) concentrations in serum and plasma, as well as transcripts in left ventricular heart tissue for atrial natriuretic peptide precursor (Nppa), brain natriuretic peptide precursor (Nppb), and myosin heavy chain-beta (Myh7) as potential biomarkers of LVH induced by a PPARalpha/gamma dual agonist in Sprague-Dawley rats. We used magnetic resonance imaging, echocardiography, and hemodynamics to identify structural and functional cardiovascular changes related to the biomarkers. Heart-to-brain weight ratios (HW:BrW) were correlated with NTproANP, NTproBNP, and cTnI concentrations in serum as well as fold change in expression of Nppa and Nppb. LVH was characterized by increased left ventricular wall thickness and inner diameter, increased cardiac output, decreased arterial blood pressure, and increased heart rate. In these studies, each end point contributed to the early detection of LVH, the ability to monitor its progression, and demonstrated the ability of NTproANP concentration in serum to predict LVH and hemodynamic changes.
Engle et al. (Thu,) conducted a other in Left ventricular hypertrophy. Peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonist was evaluated on Detection of left ventricular hypertrophy and hemodynamic changes. Measurement of serum NTproANP concentration successfully predicted left ventricular hypertrophy and hemodynamic changes in Sprague-Dawley rats administered a PPARalpha/gamma dual agonist.